De-escalation Strategy in Seminoma: An Alternative Option?
Rishi sharma last edited by
Seminoma, the commonest type of testicular cancer, has a great treatment success rate, with 3-year progression-free survival (PFS) rates of at least 90%. However, the treatment regimen is intense, comprising combination chemotherapy and large-volume radiation therapy, with their associated toxicities. A new trial (SAKK 01/10) that tested a de-escalated treatment strategy, with lower chemotherapy doses and reduced radiation therapy, has shown a favorable 3-year PFS — similar to that seen with standard-of-care approaches, but with minimal toxic effects.
@rishi-sharma De-escalation strategies in stage IIA and IIB seminoma are a current unmet clinical need and could be implemented in the coming years. The efficacy of the de-escalation strategy used in this trial suggests that it could be a valid alternative for some patients.